MedTrace Logo

Efficacy of High-oleic Canola and Flaxseed Oils for Hypercholesterolemia and Cardiovascular Disease Risk Factors

NCT00927199 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2013-02-01

No results posted yet for this study

Summary

The purpose of this study is to assess the efficacy of high-oleic canola oil and a high-oleic canola/flaxseed oil blend as compared to a typical Western diet on plasma lipids, fatty acid profiles, and risk factors associated with cardiovascular disease in hypercholesterolemic patients. Furthermore, the metabolism of dietary oleic acid and alpha-linolenic acid contained in high-oleic canola oil and flaxseed oil will be investigated.

Conditions

Interventions

DIETARY_SUPPLEMENT

High-Oleic Canola Oil

Diets contained 35% energy as fat; of which 70% was provided by high-oleic canola oil (high in monounsaturated fat (oleic acid))

DIETARY_SUPPLEMENT

High-Oleic Canola/Flaxseed Oil Blend

Diets contained 35% energy as fat; of which 70% was provided by a 1:1 blend of high-oleic canola oil and flaxseed oil (high in monounsaturated fat (oleic acid) and omega-3 polyunsaturated fat (alpha-linolenic acid))

DIETARY_SUPPLEMENT

Western Dietary Control

Diets contained 35% energy as fat; of which 70% was provided by a blend of oils typical to the Western diet (high in saturated fat and omega-6 polyunsaturated fat (linoleic acid))

Sponsors & Collaborators

  • Canola Council of Canada

    collaborator OTHER

  • Flax Canada 2015 Inc.

    collaborator INDUSTRY

  • Agri-Food Research and Development Initiative

    collaborator UNKNOWN

  • University of Manitoba

    lead OTHER

Principal Investigators

  • Peter JH Jones, PhD · University of Manitoba - Richardson Centre for Functional Foods and Nutraceuticals

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-09-30
Primary Completion
2008-06-30
Completion
2008-06-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00927199 on ClinicalTrials.gov